



(51) International Patent Classification:

A61K 31/42 (2006.01) A61K 45/06 (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:

PCT/US2015/051529

(22) International Filing Date:

22 September 2015 (22.09.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/054,767 24 September 2014 (24.09.2014) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventor: WATKINS, William, J.; C/o Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(74) Agents: POLSTER, Philip, B. et al.; Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: METHODS OF TREATING LIVER DISEASE

(57) Abstract: The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an
ASK1 inhibitor in combination with a FXR agonist, to a patient in need thereof.



METHODS OF TREATING LIVER DISEASE

FIELD

The present disclosure relates to a method of preventing and/or treating liver
5 disease.

BACKGROUND

Liver disease is generally classified as acute or chronic based upon the duration
of the disease. Liver disease may be caused by infection, injury, exposure to drugs or
toxic compounds, alcohol, impurities in foods, and the abnormal build-up of normal
10 substances in the blood, an autoimmune process, a genetic defect (such as
haemochromatosis), or unknown cause(s).

Liver disease is a leading cause of death world wide. In particular, it has been
seen that a diet high in fat damages the liver in ways that are surprisingly similar to
hepatitis. The American Liver Foundation estimates that more than 20 percent of the
15 population has non-alcoholic fatty liver disease (NAFLD). It is suggested that obesity,
unhealthy diets, and sedentary lifestyles may contribute to the high prevalence of
NAFLD. When left untreated, NAFLD can progress to non-alcoholic steatohepatitis
(NASH) causing serious adverse effects. Once NASH is developed, it would cause the
liver to swell and scar (i.e. cirrhosis) over time.

20 Although preliminary reports suggest positive lifestyle changes could prevent or
reverse liver damage, there are no effective medical treatments for NAFLD.
Accordingly, there remains a need to provide new effective pharmaceutical agents to
treat liver diseases.

SUMMARY

25 Disclosed herein is a method of treating and/or preventing liver disease in a
patient in need thereof, comprising administering to the patient a therapeutically effective
amount of an apoptosis signal regulating kinase 1 (ASK1) inhibitor in combination with
a therapeutically effective amount of farnesoid X receptor (FXR) agonist. The liver
disease can be any liver disease, including, but not limited to, chronic and/or metabolic
30 liver diseases, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic
steatohepatitis (NASH).

In certain embodiments, provided herein is a method of treating and/or preventing nonalcoholic steatohepatitis (NASH) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an ASK1 inhibitor in combination with a therapeutically effective amount of a FXR agonist.

5 In the methods provided herein, the ASK1 inhibitor and the FXR agonist can be coadministered. In such embodiments, the ASK1 inhibitor and the FXR agonist can be administered together as a single pharmaceutical composition, or separately in more than one pharmaceutical composition. Accordingly, also provided herein is a pharmaceutical composition comprising a therapeutically effective amount of an ASK1 inhibitor and a
10 therapeutically effective amount of a FXR agonist.

DETAILED DESCRIPTION

Definitions and General Parameters

As used in the present specification, the following terms and phrases are generally intended to have the meanings as set forth below, except to the extent that the
15 context in which they are used indicates otherwise.

As used herein, the term “about” used in the context of quantitative measurements means the indicated amount $\pm 10\%$, or alternatively the indicated amount $\pm 5\%$ or $\pm 1\%$.

As referred to herein, an “ASK1 inhibitor” may be any agent that is capable of
20 inactivating an apoptosis signal regulating kinase 1 (ASK1) protein. The agent may be a chemical compound or biological molecule (e.g., a protein or antibody). The ASK1 protein activity may be measured by several different methods. For example, the activity of an ASK1 protein may be determined based on the ability of the ASK1 protein to phosphorylate a substrate protein. Methods for identifying an ASK1 inhibitor are known
25 (see, e.g., U.S. 2007/0276050 and U.S. 2011/0009410, both of which are incorporated herein by reference in their entirety). Exemplary ASK1 substrate proteins include MAPKK3, MAPKK4, MAPKK6, MAPKK7, or fragments thereof. The ASK1 protein activity may also be measured by the phosphorylation level of the ASK1 protein, for example, the phosphorylation level of a threonine residue in the ASK1 protein
30 corresponding to threonine 838 (T838) of a human full-length ASK1 protein or threonine 845 (T845) of a mouse full-length ASK1 protein. For example, where the ASK1 protein

comprises a full-length human ASK1 protein sequence, an ASK1 inhibitor may attenuate phosphorylation of T838 in the full-length human ASK1 protein sequence. A site specific antibody against human ASK1 T838 or mouse ASK1 T845 may be used to detect the phosphohorylation level.

5 As used herein, a “FXR agonist” refers to any agent that is capable of binding and activating farnesoid X receptor (FXR) which may be referred to as bile acid receptor (BAR) or NR1H4 (nuclear receptor subfamily 1, group H, member 4) receptor. FXR agonist may act as agonists or partial agonists of FXR. The agent may be a chemical compound or biological molecule (e.g., a protein or antibody). The activity of a FXR
10 agonist may be measured by several different methods, e.g. in an *in vitro* assay using the fluorescence resonance energy transfer (FRET) cell free assay as described in Pellicciari, et al. *Journal of Medicinal Chemistry*, 2002 vol. 15, No. 45:3569-72.

 The term “pharmaceutically acceptable salt” refers to salts of pharmaceutical compounds e.g. compound of formula (I) that retain the biological effectiveness and
15 properties of the underlying compound, and which are not biologically or otherwise undesirable. There are acid addition salts and base addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids.

 Acids and bases useful for reaction with an underlying compound to form pharmaceutically acceptable salts (acid addition or base addition salts respectively) are
20 known to one of skill in the art. Similarly, methods of preparing pharmaceutically acceptable salts from an underlying compound (upon disclosure) are known to one of skill in the art and are disclosed in for example, Berge, et al. *Journal of Pharmaceutical Science*, Jan. 1977 vol. 66, No.1, and other sources.

 As used herein, “pharmaceutically acceptable carrier” includes excipients or
25 agents such as solvents, diluents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like that are not deleterious to the disclosed compound or use thereof. The use of such carriers and agents to prepare compositions of pharmaceutically active substances is well known in the art (see, e.g., Remington’s *Pharmaceutical Sciences*, Mace Publishing Co., Philadelphia, PA 17th Ed. (1985); and *Modern Pharmaceutics*, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).
30

The terms “therapeutically effective amount” and “effective amount” are used interchangeably and refer to an amount of a compound that is sufficient to effect treatment as defined below, when administered to a patient (e.g., a human) in need of such treatment in one or more doses. The therapeutically effective amount will vary
5 depending upon the patient, the disease being treated, the weight and/or age of the patient, the severity of the disease, or the manner of administration as determined by a qualified prescriber or care giver.

The term “treatment” or “treating” means administering a compound or pharmaceutically acceptable salt of formula (I) for the purpose of: (i) delaying the onset
10 of a disease, that is, causing the clinical symptoms of the disease not to develop or delaying the development thereof; (ii) inhibiting the disease, that is, arresting the development of clinical symptoms; and/or (iii) relieving the disease, that is, causing the regression of clinical symptoms or the severity thereof.

The term “alkyl” refers to a monoradical branched or unbranched saturated
15 hydrocarbon chain having from 1 to 20 carbon atoms, or from 1 to 15 carbon atoms, or from 1 to 10 carbon atoms, or from 1 to 8 carbon atoms, or from 1 to 6 carbon atoms, or from 1 to 4 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-hexyl, n-decyl, tetradecyl, and the like.

The term “substituted alkyl” refers to:

20 1) an alkyl group as defined above, having 1, 2, 3, 4 or 5 substituents, (in some embodiments, 1, 2 or 3 substituents) selected from the group consisting of alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio,
25 heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)₂-alkyl, -S(O)₂-cycloalkyl, -S(O)₂-heterocyclyl, -S(O)₂-aryl and -S(O)₂-heteroaryl. Unless otherwise constrained by the definition, all substituents may
30 optionally be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF₃, amino,

substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and $-S(O)_nR^a$, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2; or

- 2) an alkyl group as defined above that is interrupted by 1-10 atoms (e.g. 1, 2, 3, 4 or 5 atoms) independently chosen from oxygen, sulfur and NR^a , where R^a is
 5 chosen from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. All substituents may be optionally further substituted by alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF_3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and $-S(O)_nR^a$, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2; or
 10 3) an alkyl group as defined above that has both 1, 2, 3, 4 or 5 substituents as defined above and is also interrupted by 1-10 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above.

The term “lower alkyl” refers to a monoradical branched or unbranched saturated hydrocarbon chain having 1, 2, 3, 4, 5 or 6 carbon atoms. This term is exemplified by
 15 groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-hexyl, and the like.

The term “substituted lower alkyl” refers to lower alkyl as defined above having 1 to 5 substituents (in some embodiments, 1, 2 or 3 substituents), as defined for substituted alkyl or a lower alkyl group as defined above that is interrupted by 1, 2, 3, 4
 20 or 5 atoms as defined for substituted alkyl or a lower alkyl group as defined above that has both 1, 2, 3, 4 or 5 substituents as defined above and is also interrupted by 1, 2, 3, 4 or 5 atoms as defined above.

The term “alkylene” refers to a diradical of a branched or unbranched saturated hydrocarbon chain, in some embodiments, having from 1 to 20 carbon atoms (e.g. 1-10
 25 carbon atoms or 1, 2, 3, 4, 5 or 6 carbon atoms). This term is exemplified by groups such as methylene ($-CH_2-$), ethylene ($-CH_2CH_2-$), the propylene isomers (e.g., $-CH_2CH_2CH_2-$ and $-CH(CH_3)CH_2-$), and the like.

The term “lower alkylene” refers to a diradical of a branched or unbranched saturated hydrocarbon chain, in some embodiments, having 1, 2, 3, 4, 5 or 6 carbon
 30 atoms.

The term “substituted alkylene” refers to an alkylene group as defined above having 1 to 5 substituents (in some embodiments, 1, 2 or 3 substituents) as defined for substituted alkyl.

5 The term “aralkyl” refers to an aryl group covalently linked to an alkylene group, where aryl and alkylene are defined herein. “Optionally substituted aralkyl” refers to an optionally substituted aryl group covalently linked to an optionally substituted alkylene group. Such aralkyl groups are exemplified by benzyl, phenylethyl, 3-(4-methoxyphenyl)propyl, and the like.

10 The term “aralkyloxy” refers to the group -O-aralkyl. “Optionally substituted aralkyloxy” refers to an optionally substituted aralkyl group covalently linked to an optionally substituted alkylene group. Such aralkyl groups are exemplified by benzyloxy, phenylethyloxy, and the like.

15 The term “alkenyl” refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group having from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from 1 to 6 carbon-carbon double bonds, e.g. 1, 2 or 3 carbon-carbon double bonds. In some embodiments, alkenyl groups include ethenyl (or vinyl, i.e. $-\text{CH}=\text{CH}_2$), 1-propylene (or allyl, i.e. $-\text{CH}_2\text{CH}=\text{CH}_2$), isopropylene ($-\text{C}(\text{CH}_3)=\text{CH}_2$), and the like.

20 The term “lower alkenyl” refers to alkenyl as defined above having from 2 to 6 carbon atoms.

The term “substituted alkenyl” refers to an alkenyl group as defined above having 1 to 5 substituents (in some embodiments, 1, 2 or 3 substituents) as defined for substituted alkyl.

25 The term “alkenylene” refers to a diradical of a branched or unbranched unsaturated hydrocarbon group having from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from 1 to 6 carbon-carbon double bonds, e.g. 1, 2 or 3 carbon-carbon double bonds.

30 The term “alkynyl” refers to a monoradical of an unsaturated hydrocarbon, in some embodiments, having from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from 1 to 6 carbon-carbon triple

bonds e.g. 1, 2 or 3 carbon-carbon triple bonds. In some embodiments, alkynyl groups include ethynyl ($-C\equiv CH$), propargyl (or propynyl, i.e. $-C\equiv CCH_3$), and the like.

The term “substituted alkynyl” refers to an alkynyl group as defined above having 1 to 5 substituents (in some embodiments, 1, 2 or 3 substituents) as defined for
5 substituted alkyl.

The term “alkynylene” refers to a diradical of an unsaturated hydrocarbon, in some embodiments, having from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from 1 to 6 carbon-carbon triple bonds e.g. 1, 2 or 3 carbon-carbon triple bonds.

10 The term “hydroxy” or “hydroxyl” refers to a group $-OH$.

The term “alkoxy” refers to the group $R-O-$, where R is alkyl or $-Y-Z$, in which Y is alkylene and Z is alkenyl or alkynyl, where alkyl, alkenyl and alkynyl are as defined herein. In some embodiments, alkoxy groups are alkyl- $O-$ and includes, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy,
15 n-pentoxy, n-hexyloxy, 1,2-dimethylbutoxy, and the like.

The term “lower alkoxy” refers to the group $R-O-$ in which R is optionally substituted lower alkyl. This term is exemplified by groups such as methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, n-hexyloxy, and the like.

The term “substituted alkoxy” refers to the group $R-O-$, where R is substituted
20 alkyl or $-Y-Z$, in which Y is substituted alkylene and Z is substituted alkenyl or substituted alkynyl, where substituted alkyl, substituted alkenyl and substituted alkynyl are as defined herein.

The term “ C_{1-3} haloalkyl” refers to an alkyl group having from 1 to 3 carbon atoms covalently bonded to from 1 to 7, or from 1 to 6, or from 1 to 3, halogen(s), where
25 alkyl and halogen are defined herein. In some embodiments, C_{1-3} haloalkyl includes, by way of example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, 3,3-difluoropropyl, 3-fluoropropyl.

The term “ C_{1-3} hydroxyalkyl” refers to an alkyl group having a carbon atom covalently bonded to a hydroxy, where alkyl and hydroxy are defined herein. In some
30 embodiments, C_{1-3} hydroxyalkyl includes, by way of example, 2-hydroxyethyl.

The term “C₁₋₃ cyanoalkyl” refers to an alkyl group having a carbon atom covalently bonded to a cyano, where alkyl and cyano are defined herein. In some embodiments, C₁₋₃ cyanoalkyl includes, by way of example, 2-cyanoethyl.

The term “cycloalkyl” refers to cyclic alkyl groups of from 3 to 20 carbon atoms, or from 3 to 10 carbon atoms, having a single cyclic ring or multiple condensed rings. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl and the like or multiple ring structures such as adamantanyl and bicyclo[2.2.1]heptanyl or cyclic alkyl groups to which is fused an aryl group, for example indanyl, and the like, provided that the point of attachment is through the cyclic alkyl group.

The term “cycloalkenyl” refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings and having at least one double bond and in some embodiments, from 1 to 2 double bonds.

The terms “substituted cycloalkyl” and “substituted cycloalkenyl” refer to cycloalkyl or cycloalkenyl groups having 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)₂-alkyl, -S(O)₂-cycloalkyl, -S(O)₂-heterocyclyl, -S(O)₂-aryl and -S(O)₂-heteroaryl. The term “substituted cycloalkyl” also includes cycloalkyl groups wherein one or more of the annular carbon atoms of the cycloalkyl group has an oxo group bonded thereto. In addition, a substituent on the cycloalkyl or cycloalkenyl may be attached to the same carbon atom as, or is geminal to, the attachment of the substituted cycloalkyl or cycloalkenyl to the 6,7-ring system. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF₃, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)_nR^a, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

The term “cycloalkoxy” refers to the group cycloalkyl-O-.

The term “substituted cycloalkoxy” refers to the group substituted cycloalkyl-O-.

The term “cycloalkenyloxy” refers to the group cycloalkenyl-O-.

The term “substituted cycloalkenyloxy” refers to the group substituted
5 cycloalkenyl-O-.

The term “aryl” refers to an aromatic carbocyclic group of 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple rings (e.g., biphenyl) or multiple condensed (fused) rings (e.g., naphthyl, fluorenyl and anthryl). In some embodiments, aryls include phenyl, fluorenyl, naphthyl, anthryl, and the like.

10 Unless otherwise constrained by the definition for the aryl substituent, such aryl groups can optionally be substituted with 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxy-carbonylamino,
15 azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)₂-alkyl, -S(O)₂-cycloalkyl, -S(O)₂-heterocyclyl, -S(O)₂-aryl and -S(O)₂-
20 heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF₃, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)_nR^a, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

25 The term “aryloxy” refers to the group aryl-O- wherein the aryl group is as defined above, and includes optionally substituted aryl groups as also defined above. The term “arylthio” refers to the group R-S-, where R is as defined for aryl.

The term “heterocyclyl,” “heterocycle,” or “heterocyclic” refers to a monoradical saturated group having a single ring or multiple condensed rings, having from 1 to 40
30 carbon atoms and from 1 to 10 hetero atoms, and from 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within the ring. In some embodiments, the

heterocyclyl,” “heterocycle,” or “heterocyclic” group is linked to the remainder of the molecule through one of the heteroatoms within the ring.

Unless otherwise constrained by the definition for the heterocyclic substituent, such heterocyclic groups can be optionally substituted with 1 to 5 substituents (in some
5 embodiments, 1, 2 or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl,
10 aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)₂-alkyl, -S(O)₂-cycloalkyl, -S(O)₂-heterocyclyl, -S(O)₂-aryl and -S(O)₂-heteroaryl. In addition, a substituent on the heterocyclic group may be attached to the same carbon atom as, or is geminal to, the attachment of the substituted heterocyclic
15 group to the 6,7-ring system. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF₃, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)_nR^a, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2. Examples of
20 heterocyclics include tetrahydrofuranyl, morpholino, piperidiny, and the like.

The term “heterocycloxy” refers to the group -O-heterocyclyl.

The term “heteroaryl” refers to a group comprising single or multiple rings comprising 1 to 15 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within at least one ring. The term “heteroaryl” is generic to the terms
25 “aromatic heteroaryl” and “partially saturated heteroaryl”. The term “aromatic heteroaryl” refers to a heteroaryl in which at least one ring is aromatic, regardless of the point of attachment. Examples of aromatic heteroaryls include pyrrole, thiophene, pyridine, quinoline, pteridine.

The term “partially saturated heteroaryl” refers to a heteroaryl having a structure
30 equivalent to an underlying aromatic heteroaryl which has had one or more double bonds in an aromatic ring of the underlying aromatic heteroaryl saturated. Examples of

partially saturated heteroaryls include dihydropyrrole, dihydropyridine, chroman, 2-oxo-1,2-dihydropyridin-4-yl, and the like.

Unless otherwise constrained by the definition for the heteroaryl substituent, such heteroaryl groups can be optionally substituted with 1 to 5 substituents (in some
 5 embodiments, 1, 2 or 3 substituents) selected from the group consisting alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl,
 10 aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)₂-alkyl, -S(O)₂-cycloalkyl, -S(O)₂-heterocyclyl, -S(O)₂-aryl and -S(O)₂-heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl,
 15 alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF₃, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)_nR^a, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2. Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indoliziny, benzothiazole or benzothieryl). Examples of nitrogen heterocyclyls and heteroaryls
 20 include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine,
 25 imidazoline, and the like as well as N-alkoxy-nitrogen containing heteroaryl compounds.

The term “heteroaryloxy” refers to the group heteroaryl-O-.

The term “amino” refers to the group -NH₂.

The term “substituted amino” refers to the group -NRR where each R is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl,
 30 heteroaryl and heterocyclyl provided that both R groups are not hydrogen or a group -Y-Z, in which Y is optionally substituted alkylene and Z is alkenyl, cycloalkenyl or alkynyl. Unless otherwise constrained by the definition, all substituents may optionally

be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF₃, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)_nR^a, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

5 The term “alkyl amine” refers to R-NH₂ in which R is optionally substituted alkyl.

The term “dialkyl amine” refers to R-NHR in which each R is independently an optionally substituted alkyl.

10 The term “trialkyl amine” refers to NR₃ in which each R is independently an optionally substituted alkyl.

The term “cyano” refers to the group -CN.

The term “azido” refers to a group $\text{—}\overset{\oplus}{\text{N}}=\overset{\ominus}{\text{N}}=\overset{\ominus}{\text{N}}$.

The term “keto” or “oxo” refers to a group =O.

The term “carboxy” refers to a group -C(O)-OH.

15 The term “ester” or “carboxyester” refers to the group -C(O)OR, where R is alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, which may be optionally further substituted by alkyl, alkoxy, halogen, CF₃, amino, substituted amino, cyano or -S(O)_nR^a, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

20 The term “acyl” denotes the group -C(O)R, in which R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF₃, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)_nR^a, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

25 The term “carboxyalkyl” refers to the groups -C(O)O-alkyl or -C(O)O-cycloalkyl, where alkyl and cycloalkyl are as defined herein, and may be optionally further substituted by alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF₃, amino, substituted amino, cyano, cycloalkyl,

heterocyclyl, aryl, heteroaryl, and $-S(O)_nR^a$, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

The term “aminocarbonyl” refers to the group $-C(O)NRR$ where each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, or where
5 both R groups are joined to form a heterocyclic group (e.g., morpholino). Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF_3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and $-S(O)_nR^a$, in
10 which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

The term “acyloxy” refers to the group $-OC(O)-R$, in which R is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl,
15 aminocarbonyl, hydroxy, alkoxy, halogen, CF_3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and $-S(O)_nR^a$, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

The term “acylamino” refers to the group $-NRC(O)R$ where each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. Unless
20 otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF_3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and $-S(O)_nR^a$, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

The term “alkoxycarbonylamino” refers to the group $-N(R^d)C(O)OR$ in which R is alkyl and R^d is hydrogen or alkyl. Unless otherwise constrained by the definition, each alkyl may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF_3 , amino, substituted amino, cyano, cycloalkyl,
25 heterocyclyl, aryl, heteroaryl, and $-S(O)_nR^a$, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.
30

The term “aminocarbonylamino” refers to the group $\text{-NR}^c\text{C(O)NRR}$, wherein R^c is hydrogen or alkyl and each R is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents selected from the group
5 consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF_3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and $\text{-S(O)}_n\text{R}^a$, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

The term “thiol” refers to the group -SH .

The term “thiocarbonyl” refers to a group =S .

10 The term “alkylthio” refers to the group -S-alkyl .

The term “substituted alkylthio” refers to the group $\text{-S-substituted alkyl}$.

The term “heterocyclylthio” refers to the group -S-heterocyclyl .

The term “arylthio” refers to the group -S-aryl .

The term “heteroarylthiol” refers to the group -S-heteroaryl wherein the
15 heteroaryl group is as defined above including optionally substituted heteroaryl groups as also defined above.

The term “sulfoxide” refers to a group -S(O)R , in which R is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. “Substituted sulfoxide” refers to a group -S(O)R , in which R is substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted
20 aryl or substituted heteroaryl, as defined herein.

The term “sulfone” refers to a group $\text{-S(O)}_2\text{R}$, in which R is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. “Substituted sulfone” refers to a group $\text{-S(O)}_2\text{R}$, in which R is substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl or substituted heteroaryl, as defined herein.

25 The term “aminosulfonyl” refers to the group $\text{-S(O)}_2\text{NRR}$, wherein each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF_3 , amino,
30 substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and $\text{-S(O)}_n\text{R}^a$, in which R^a is alkyl, aryl or heteroaryl and n is 0, 1 or 2.

The term “hydroxyamino” refers to the group –NHOH.

The term “alkoxyamino” refers to the group –NHOR in which R is optionally substituted alkyl.

The term “halogen” or “halo” refers to fluoro, bromo, chloro and iodo.

5 “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.

A “substituted” group includes embodiments in which a monoradical substituent is bound to a single atom of the substituted group (e.g. forming a branch), and also
10 includes embodiments in which the substituent may be a diradical bridging group bound to two adjacent atoms of the substituted group, thereby forming a fused ring on the substituted group.

Where a given group (moiety) is described herein as being attached to a second group and the site of attachment is not explicit, the given group may be attached at any
15 available site of the given group to any available site of the second group. For example, a “lower alkyl-substituted phenyl”, where the attachment sites are not explicit, may have any available site of the lower alkyl group attached to any available site of the phenyl group. In this regard, an “available site” is a site of the group at which a hydrogen of the group may be replaced with a substituent.

20 It is understood that in all substituted groups defined above, polymers arrived at by defining substituents with further substituents to themselves (e.g., substituted aryl having a substituted aryl group as a substituent which is itself substituted with a substituted aryl group, etc.) are not intended for inclusion herein. Also not included are infinite numbers of substituents, whether the substituents are the same or different. In
25 such cases, the maximum number of such substituents is three. Each of the above definitions is thus constrained by a limitation that, for example, substituted aryl groups are limited to -substituted aryl-(substituted aryl)-substituted aryl.

Liver Diseases

30 Liver diseases are acute or chronic damages to the liver based in the duration of the disease. The liver damage may be caused by infection, injury, exposure to drugs or toxic compounds such as alcohol or impurities in foods, an abnormal build-up of normal

substances in the blood, an autoimmune process, a genetic defect (such as haemochromatosis), or other unknown causes. Exemplary liver diseases include, but are not limited to, cirrhosis, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), hepatic ischemia
5 reperfusion injury, primary biliary cirrhosis (PBC), and hepatitis, including both viral and alcoholic hepatitis.

Non-alcoholic fatty liver disease (NAFLD) is the build up of extra fat in liver cells that is not caused by alcohol. NAFLD may cause the liver to swell (i.e. steatohepatitis), which in turn may cause scarring (i.e. cirrhosis) over time and may lead
10 to liver cancer or liver failure. NAFLD is characterized by the accumulation of fat in hepatocytes and is often associated with some aspects of metabolic syndrome (e.g. type 2 diabetes mellitus, insulin resistance, hyperlipidemia, hypertension). The frequency of this disease has become increasingly common due to consumption of carbohydrate-rich and high fat diets. A subset (~20%) of NAFLD patients develop nonalcoholic
15 steatohepatitis (NASH).

NASH, a subtype of fatty liver disease, is the more severe form of NAFLD. It is characterized by macrovesicular steatosis, balloon degeneration of hepatocytes, and/or inflammation ultimately leading to hepatic scarring (i.e. fibrosis). Patients diagnosed with NASH progress to advanced stage liver fibrosis and eventually cirrhosis. The
20 current treatment for cirrhotic NASH patients with end-stage disease is liver transplant.

A study has shown that a significant proportion of diagnosed NASH patients (39%) have not had a liver biopsy to confirm the diagnosis. A greater proportion of diagnosed NASH patients have metabolic syndrome parameters than what is reported in the literature (type-II diabetes mellitus 54%, Obesity 71%, metabolic syndrome 59%).
25 82% of physicians use a lower threshold value to define significant alcohol consumption compared with practice guideline recommendations. 88% of physicians prescribe some form of pharmacologic treatment for NASH (Vit E: prescribed to 53% of NASH patients, statins: 57%, metformin: 50%). Therefore, the vast majority of patients are prescribed medications despite a lack of a confirmed diagnosis or significant data to
30 support the intervention and alcohol thresholds to exclude NASH are lower than expected.

Another common liver disease is primary sclerosing cholangitis (PSC). It is a chronic or long-term liver disease that slowly damages the bile ducts inside and outside the liver. In patients with PSC, bile accumulates in the liver due to blocked bile ducts, where it gradually damages liver cells and causes cirrhosis, or scarring of the liver.

- 5 Currently, there is no effective treatment to cure PSC. Many patients having PSC ultimately need a liver transplant due to liver failure, typically about 10 years after being diagnosed with the disease. PSC may also lead to bile duct cancer.

- 10 Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation.

Methods

- Disclosed herein is a method of treating and/or preventing liver disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an ASK1 inhibitor in combination with a therapeutically effective amount of a FXR agonist. The presence of active liver disease can be detected by the existence of elevated enzyme levels in the blood. Specifically, blood levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), above clinically accepted normal ranges, are known to be indicative of on-going liver damage. Routine monitoring of liver disease patients for blood levels of ALT and AST is used clinically to measure progress of the liver disease while on medical treatment. Reduction of elevated ALT and AST to within the accepted normal range is taken as clinical evidence reflecting a reduction in the severity of the patients on-going liver damage.

- 25 In certain embodiments, the liver disease is a chronic liver disease. Chronic liver diseases involve the progressive destruction and regeneration of the liver parenchyma, leading to fibrosis and cirrhosis. In general, chronic liver diseases can be caused by viruses (such as hepatitis B, hepatitis C, cytomegalovirus (CMV), or Epstein Barr Virus (EBV)), toxic agents or drugs (such as alcohol, methotrexate, or nitrofurantoin), a metabolic disease (such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), haemochromatosis, or Wilson's Disease), an autoimmune disease (such as Autoimmune Chronic Hepatitis, Primary Biliary Cirrhosis, or Primary Sclerosing Cholangitis), or other causes (such as right heart failure).

In one embodiment, provided herein is a method for reducing the level of cirrhosis. In one embodiment, cirrhosis is characterized pathologically by loss of the normal microscopic lobular architecture, with fibrosis and nodular regeneration. Methods for measuring the extent of cirrhosis are well known in the art. In one
5 embodiment, the level of cirrhosis is reduced by about 5% to about 100%. In one embodiment, the level of cirrhosis is reduced by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about
10 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% in the subject.

In certain embodiments, the liver disease is a metabolic liver disease. In one embodiment, the liver disease is non-alcoholic fatty liver disease (NAFLD). NAFLD is associated with insulin resistance and metabolic syndrome (obesity, combined
15 hyperlipidemia, diabetes mellitus (type II) and high blood pressure). NAFLD is considered to cover a spectrum of disease activity, and begins as fatty accumulation in the liver (hepatic steatosis).

It has been shown that both obesity and insulin resistance probably play a strong role in the disease process of NAFLD. In addition to a poor diet, NAFLD has several
20 other known causes. For example, NAFLD can be caused by certain medications, such as amiodarone, antiviral drugs (e.g., nucleoside analogues), aspirin (rarely as part of Reye's syndrome in children), corticosteroids, methotrexate, tamoxifen, or tetracycline. NAFLD has also been linked to the consumption of soft drinks through the presence of high fructose corn syrup which may cause increased deposition of fat in the abdomen,
25 although the consumption of sucrose shows a similar effect (likely due to its breakdown into fructose). Genetics has also been known to play a role, as two genetic mutations for this susceptibility have been identified.

If left untreated, NAFLD can develop into non-alcoholic steatohepatitis (NASH), which is the most extreme form of NAFLD, a state in which steatosis is combined with
30 inflammation and fibrosis. NASH is regarded as a major cause of cirrhosis of the liver of unknown cause. Accordingly, provided herein is a method of treating and/or preventing nonalcoholic steatohepatitis (NASH) in a patient in need thereof, comprising

administering to the patient a therapeutically effective amount of an ASK1 inhibitor in combination with a therapeutically effective amount of a FXR agonist.

Also provided herein is a method of treating and/or preventing liver fibrosis in a patient in need thereof, comprising administering to the patient a therapeutically effective
5 amount of an ASK1 inhibitor in combination with a therapeutically effective amount of a FXR agonist. Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. In certain embodiments, advanced liver fibrosis results in cirrhosis and liver failure. Methods for measuring liver histologies, such as changes in the extent of fibrosis, lobular hepatitis,
10 and periportal bridging necrosis, are well known in the art.

In one embodiment, the level of liver fibrosis, which is the formation of fibrous tissue, fibroid or fibrous degeneration, is reduced by more than about 90%. In one embodiment, the level of fibrosis, which is the formation of fibrous tissue, fibroid or fibrous degeneration, is reduced by at least about 90%, at least about 80%, at least about
15 70%, at least about 60%, at least about 50%, at least about 40%, at least about 30%, at least about 20%, at least about 10%, at least about 5% or at least about 2%.

In one embodiment, the compounds provided herein reduce the level of fibrogenesis in the liver. Liver fibrogenesis is the process leading to the deposition of an excess of extracellular matrix components in the liver known as fibrosis. It is observed
20 in a number of conditions such as chronic viral hepatitis B and C, alcoholic liver disease, drug-induced liver disease, hemochromatosis, auto-immune hepatitis, Wilson disease, primary biliary cirrhosis, sclerosing cholangitis, liver schistosomiasis and others. In one embodiment, the level of fibrogenesis is reduced by more than about 90%. In one embodiment, the level of fibrogenesis is reduced by at least about 90%, at least about
25 80%, at least about 70%, at least about 60%, at least about 50%, at least about 40%, at least about 30%, at least about 20%, at least about 10%, at least about 5% or at least about 2%.


In still other embodiments, provided herein is a method of treating and/or preventing primary sclerosing cholangitis (PSC) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an ASK1 inhibitor in
30 combination with a therapeutically effective amount of a FXR agonist.

ASK1 Inhibitors

An ASK1 inhibitor for use in the methods and pharmaceutical compositions disclosed herein may be any chemical compound or biological molecule (e.g., a protein or antibody) capable of inactivating apoptosis signal regulating kinase 1 (ASK1) protein. ASK1 inhibitors for use in the methods described herein are known (see, e.g., U.S.

5 Patent Application Publication Nos. 2011/0009410, 2013/0197037, 2013/0197037, 2014/0179663, and 2014/0018370, all of which are incorporated herein by reference in their entirety) and/or can be identified via known methods (see, e.g., U.S. Patent Application Publication Nos. 2007/0276050 and 2011/0009410, which are incorporated herein by reference in their entirety).

10 In certain embodiments, the ASK1 inhibitor is a compound having the structure of formula (I):



wherein:

R^1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein
 15 the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to three substituents selected from halo, oxo, alkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, $-NO_2$, R^6 , $-C(O)-R^6$, $-OC(O)-R^6-C(O)-O-R^6$, $C(O)-N(R^6)(R^7)$, $-OC(O)-N(R^6)(R^7)$, $-S-R^6$, $-S(=O)-R^6$, $-S(=O)_2R^6$, $-S(=O)_2-N(R^6)(R^7)$, $-S(=O)_2-O-R^6$, $-N(R^6)(R^7)$, $-N(R^6)-C(O)-R^7$, $-N(R^6)-C(O)-O-R^7$, $-N(R^6)-C(O)-N(R^6)(R^7)$, $-N(R^6)-S(=O)_2-R^6$, $-CN$, and $-O-R^6$, and wherein the alkyl, cycloalkyl, heterocyclyl, phenyl, and phenoxy are optionally substituted by from one to three substituents selected from alkyl, cycloalkyl, alkoxy, hydroxyl, and halo; wherein R^6 and R^7 are independently selected
 20 from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, all of which are optionally substituted with from one to three substituents selected from halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, $-CN$, lower alkoxy, $-CF_3$, aryl, and heteroaryl; or

R^6 and R^7 when taken together with the nitrogen to which they are attached form a heterocycle;

R^2 is hydrogen, halo, cyano, alkoxy, or alkyl optionally substituted by halo;

R^3 is aryl, heteroaryl, or heterocyclyl, wherein the aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to five substituents selected from alkyl, alkoxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, oxo, $-\text{NO}_2$, haloalkyl, haloalkoxy, $-\text{CN}$, $-\text{O}-R^6$, $-\text{O}-\text{C}(\text{O})-R^6$, $-\text{O}-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}-R^6$, $-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}(=\text{O})-R^6$, $-\text{S}(=\text{O})_2R^6$, $-\text{S}(=\text{O})_2-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}(=\text{O})_2-\text{O}-R^6$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-R^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{O}-R^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{C}(\text{O})-R^6$, $-\text{C}(\text{O})-\text{O}-R^6$, $-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, and $-\text{N}(\text{R}^6)-\text{S}(=\text{O})_2-R^7$, wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally substituted with from one to five substituents selected from halo, oxo, $-\text{NO}_2$, alkyl, haloalkyl, haloalkoxy, $-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{C}(\text{O})-R^6$, $-\text{C}(\text{O})-\text{O}-R^6$, $-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{CN}$, $-\text{O}-R^6$, cycloalkyl, aryl, heteroaryl and heterocyclyl; with the proviso that the heteroaryl or heterocyclyl moiety includes at least one ring nitrogen atom;


X^1 , X^2 , X^3 , X^4 , X^5 , X^6 , X^7 and X^8 are independently $\text{C}(\text{R}^4)$ or N , in which each R^4 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, $-\text{NO}_2$, haloalkyl, haloalkoxy, $-\text{CN}$, $-\text{O}-R^6$, $-\text{S}-R^6$, $-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}(=\text{O})-R^6$, $-\text{S}(=\text{O})_2R^6$, $-\text{S}(=\text{O})_2-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}(=\text{O})_2-\text{O}-R^6$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-R^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{O}-R^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{C}(\text{O})-R^6$, $-\text{C}(\text{O})-\text{O}-R^6$, $-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, or $-\text{N}(\text{R}^6)-\text{S}(=\text{O})_2-R^7$, wherein the alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl is further optionally substituted with from one to five substituents selected from halo, oxo, $-\text{NO}_2$, $-\text{CF}_3$, $-\text{O}-\text{CF}_3$, $-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{C}(\text{O})-R^6$, $-\text{C}(\text{O})-\text{O}-R^7$, $-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{CN}$, $-\text{O}-R^6$; or

X^5 and X^6 or X^6 and X^7 are joined to provide optionally substituted fused aryl or optionally substituted fused heteroaryl; and

with the proviso that at least one of X^2 , X^3 , and X^4 is $\text{C}(\text{R}^4)$; at least two of X^5 , X^6 , X^7 , and X^8 are $\text{C}(\text{R}^4)$; and at least one of X^2 , X^3 , X^4 , X^5 , X^6 , X^7 and X^8 is N ;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, the compound of formula (I) has the structure of formula (IA):



wherein:

R^1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to three substituents selected from halo, oxo, alkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, $-NO_2$, R^6 , $-C(O)-R^6$, $-OC(O)-R^6-C(O)-O-R^6$, $C(O)-N(R^6)(R^7)$, $-OC(O)-N(R^6)(R^7)$, $-S-R^6$, $-S(=O)-R^6$, $-S(=O)_2R^6$, $-S(=O)_2-N(R^6)(R^7)$, $-S(=O)_2-O-R^6$, $-N(R^6)(R^7)$, $-N(R^6)-C(O)-R^7$, $-N(R^6)-C(O)-O-R^7$, $-N(R^6)-C(O)-N(R^6)(R^7)$, $-N(R^6)-S(=O)_2-R^6$, $-CN$, and $-O-R^6$, and wherein the alkyl, cycloalkyl, heterocyclyl, phenyl, and phenoxy are optionally substituted by from one to three substituents selected from alkyl, cycloalkyl, alkoxy, hydroxyl, and halo; wherein R^6 and R^7 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, all of which are optionally substituted with from one to three substituents selected from halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, $-CN$, lower alkoxy, $-CF_3$, aryl, and heteroaryl; or

R^6 and R^7 when taken together with the nitrogen to which they are attached form a heterocycle;

R^8 is hydrogen, alkyl, alkoxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, oxo, $-NO_2$, haloalkyl, haloalkoxy, $-CN$, $-O-R^6$, $-O-C(O)-R^6$, $-O-C(O)-N(R^6)(R^7)$, $-S-R^6$, $-N(R^6)(R^7)$, $-S(=O)-R^6$, $-S(=O)_2R^6$, $-S(=O)_2-N(R^6)(R^7)$, $-S(=O)_2-O-R^6$, $-N(R^6)-C(O)-R^7$, $-N(R^6)-C(O)-O-R^7$, $-N(R^6)-C(O)-N(R^6)(R^7)$, $-C(O)-R^6$, $-C(O)-R^6$, $-C(O)-N(R^6)(R^7)$, and $-N(R^6)-S(=O)_2-R^7$, wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally substituted with from one to five substituents selected from halo, oxo, $-NO_2$, alkyl, haloalkyl, haloalkoxy, $-N(R^6)(R^7)$, $-C(O)-R^6$, $-C(O)-O-R^6$, $-C(O)-N(R^6)(R^7)$, $-CN$, $-O-R^6$, cycloalkyl, aryl, heteroaryl and heterocyclyl; with the proviso that the heteroaryl or heterocyclyl moiety includes at least one ring nitrogen atom;

X^2 and X^5 are independently $C(R^4)$ or N ; and


each R^4 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, $-NO_2$, haloalkyl, haloalkoxy, $-CN$, $-O-R^6$, $-S-R^6$, $-N(R^6)(R^7)$, $-S(=O)-R^6$, $-S(=O)_2R^6$, $-S(=O)_2-N(R^6)(R^7)$, $-S(=O)_2-O-R^6$, $-N(R^6)-C(O)-R^7$, $-N(R^6)-C(O)-O-R^7$, $-N(R^6)-C(O)-N(R^6)(R^7)$, $-C(O)-R^6$, $-C(O)-O-R^6$, $-C(O)-N(R^6)(R^7)$, or $-N(R^6)-S(=O)_2-R^7$, wherein the alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl is further optionally substituted with from one to five substituents selected from halo, oxo, $-NO_2$, $-CF_3$, $-O-CF_3$, $-N(R^6)(R^7)$, $-C(O)-R^6$, $-C(O)-O-R^7$, $-C(O)-N(R^6)(R^7)$, $-CN$, and $-O-R^6$;

with the proviso that at least one of X^2 and X^5 is N;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

Exemplary compounds of Formula (I) and (IA) for use in the methods and pharmaceutical compositions described herein can be found in U.S. Patent Application
 5 Publication No. 2011/0009410, which is incorporated herein by reference in its entirety.

In certain embodiments, the ASK1 inhibitor is a compound of formula (II):



wherein:

R^{21} is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl,
 10 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to four substituents selected from the group consisting of halo, hydroxyl, oxo, alkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, NO_2 , R^{26} , $C(O)R^{26}$, $OC(O)R^{26}C(O)OR^{26}$, $C(O)N(R^{26})(R^{27})$, $OC(O)N(R^{26})(R^{27})$, SR^{26} , $S(=O)R^{26}$, $S(=O)_2R^{26}$, $S(=O)_2N(R^{26})(R^{27})$, $S(=O)_2OR^{26}$, $N(R^{26})(R^{27})$, $N(R^{26})C(O)R^{27}$,
 15 $N(R^{26})C(O)OR^{27}$, $N(R^{26})C(O)N(R^{26})(R^{27})$, $N(R^{26})S(=O)_2R^{26}$, CN, and OR^{26} , wherein the alkyl, cycloalkyl, heterocyclyl, aryl, and aryloxy are optionally substituted with from one to three substituents selected from alkyl, cycloalkyl, alkoxy, hydroxyl, and halo;

R^{26} and R^{27} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, cycloalkyl,
 20 heterocyclyl, aryl, and heteroaryl are optionally substituted with from one to three substituents selected from halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, lower alkoxy, CF_3 , aryl, and heteroaryl; or

R^{26} and R^{27} when taken together with the nitrogen to which they are attached form a heterocycle;

25 R^{22} is aryl, heteroaryl, or heterocyclyl, wherein the aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to five substituents selected from alkyl, alkoxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, oxo, NO_2 , haloalkyl, haloalkoxy, CN, OR^{26} ,

OC(O)R^{26} , $\text{OC(O)N(R}^{26}\text{)(R}^{27}\text{)}$, SR^{26} , $\text{N(R}^{26}\text{)(R}^{27}\text{)}$, S(=O)R^{26} , $\text{S(=O)}_2\text{R}^{26}$,
 $\text{S(=O)}_2\text{N(R}^{26}\text{)(R}^{27}\text{)}$, $\text{S(=O)}_2\text{OR}^{26}$, $\text{N(R}^{26}\text{)C(O)R}^{27}$, $\text{N(R}^{26}\text{)C(O)OR}^{27}$,
 $\text{N(R}^{26}\text{)C(O)N(R}^{26}\text{)(R}^{27}\text{)}$, C(O)R^{26} , C(O)OR^{26} , $\text{C(O)N(R}^{26}\text{)(R}^{27}\text{)}$, and $\text{N(R}^{26}\text{)S(=O)}_2\text{R}^{27}$,
 and wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally
 5 substituted with one or more substituents selected from halo, oxo, NO_2 , alkyl, haloalkyl,
 haloalkoxy, $\text{N(R}^{26}\text{)(R}^{27}\text{)}$, C(O)R^{26} , C(O)OR^{26} , $\text{C(O)N(R}^{26}\text{)(R}^{27}\text{)}$, CN, OR^{26} , cycloalkyl,
 aryl, heteroaryl and heterocyclyl; with the proviso that the heteroaryl or heterocyclyl
 moiety includes at least one ring nitrogen atom;

R^{24} and R^{25} are independently hydrogen, halo, cyano, alkyl, alkoxy, or cycloalkyl,
 10 wherein the alkyl, alkoxy, and cycloalkyl are optionally substituted by halo or
 cycloalkyl;

X^{21} and X^{25} are independently $\text{C(R}^{23}\text{)}$ or N, wherein each R^{23} is independently
 hydrogen, halo, alkyl, alkoxy or cycloalkyl, wherein the alkyl and cycloalkyl are
 optionally substituted with from one to five substituents selected from halo, oxo, CF_3 ,
 15 OCF_3 , $\text{N(R}^{26}\text{)(R}^{27}\text{)}$, C(O)R^{26} , C(O)OR^{27} , $\text{C(O)N(R}^{26}\text{)(R}^{27}\text{)}$, CN, and OR^{26} ; and

X^{22} , X^{23} and X^{24} are independently $\text{C(R}^{23}\text{)}$, N, O, or S; with the proviso that at
 least one of X^{22} , X^{23} , and X^{24} is $\text{C(R}^{23}\text{)}$; and only one of X^{22} , X^{23} , and X^{24} is O or S;
 or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In some embodiment, the ASK1 inhibitor is the compound having the structure of
 20 formula (II), wherein:

R^{21} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, aryl, heteroaryl, or
 heterocyclyl, wherein the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, aryl,
 heteroaryl, and heterocyclyl are optionally substituted with from one to four substituents
 selected from the group consisting of halo, hydroxyl, oxo, alkyl, cycloalkyl, heterocyclyl,
 25 aryl, aryloxy, NO_2 , R^{26} , C(O)R^{26} , $\text{OC(O)R}^{26}\text{C(O)OR}^{26}$, $\text{C(O)N(R}^{26}\text{)(R}^{27}\text{)}$,
 $\text{OC(O)N(R}^{26}\text{)(R}^{27}\text{)}$, SR^{26} , S(=O)R^{26} , $\text{S(=O)}_2\text{R}^{26}$, $\text{S(=O)}_2\text{N(R}^{26}\text{)(R}^{27}\text{)}$, $\text{S(=O)}_2\text{OR}^{26}$,
 $\text{N(R}^{26}\text{)(R}^{27}\text{)}$, $\text{N(R}^{26}\text{)C(O)R}^{27}$, $\text{N(R}^{26}\text{)C(O)OR}^{27}$, $\text{N(R}^{26}\text{)C(O)N(R}^{26}\text{)(R}^{27}\text{)}$,
 $\text{N(R}^{26}\text{)S(=O)}_2\text{R}^{26}$, CN, and OR^{26} , wherein the alkyl, cycloalkyl, heterocyclyl, aryl, and
 aryloxy are optionally substituted with from one to three substituents selected from alkyl,
 30 cycloalkyl, alkoxy, hydroxyl, and halo;

R^{26} and R^{27} are independently selected from the group consisting of hydrogen,
 alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, cycloalkyl,
 heterocyclyl, aryl, and heteroaryl are optionally substituted with from one to three

substituents selected from halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, lower alkoxy, CF₃, aryl, and heteroaryl; or

R²⁶ and R²⁷ when taken together with the nitrogen to which they are attached form a heterocycle;

- 5 R²² is aryl, heteroaryl, or heterocyclyl, wherein the aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to five substituents selected from alkyl, alkoxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, oxo, NO₂, haloalkyl, haloalkoxy, CN, OR²⁶, OC(O)R²⁶, OC(O)N(R²⁶)(R²⁷), SR²⁶, N(R²⁶)(R²⁷), S(=O)R²⁶, S(=O)₂R²⁶,
 10 S(=O)₂N(R²⁶)(R²⁷), S(=O)₂OR²⁶, N(R²⁶)C(O)R²⁷, N(R²⁶)C(O)OR²⁷, N(R²⁶)C(O)N(R²⁶)(R²⁷), C(O)R²⁶, C(O)OR²⁶, C(O)N(R²⁶)(R²⁷), and N(R²⁶)S(=O)₂R²⁷,
 and wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted with one or more substituents selected from halo, oxo, NO₂, alkyl, haloalkyl, haloalkoxy, N(R²⁶)(R²⁷), C(O)R²⁶, C(O)OR²⁶, C(O)N(R²⁶)(R²⁷), CN, OR²⁶, cycloalkyl,
 15 aryl, heteroaryl and heterocyclyl; with the proviso that the heteroaryl or heterocyclyl moiety includes at least one ring nitrogen atom;


R²⁴ and R²⁵ are independently hydrogen, halo, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, or C₁₋₆ cycloalkyl, wherein the alkyl, alkoxy, and cycloalkyl are optionally substituted by halo or C₃₋₈ cycloalkyl;

- 20 X²¹ and X²⁵ are independently C(R²³) or N, wherein each R²³ is independently hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy or C₃₋₈ cycloalkyl, wherein the alkyl and cycloalkyl are optionally substituted with from one to five substituents selected from halo, oxo, CF₃, OCF₃, N(R²⁶)(R²⁷), C(O)R²⁶, C(O)OR²⁷, C(O)N(R²⁶)(R²⁷), CN, and OR²⁶; and

- 25 X²², X²³ and X²⁴ are independently C(R²³), N, O, or S; with the proviso that at least one of X²², X²³, and X²⁴ is C(R²³); and only one of X²², X²³, and X²⁴ is O or S; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

- Exemplary compounds of Formula (II) for use in the methods and pharmaceutical compositions described herein can be found in U.S. Patent Application Publication No.
 30 2012/0004267, which is incorporated herein by reference in its entirety.

In certain embodiments, the ASK1 inhibitor is a compound of formula (III):








wherein:

- R^{31} is alkyl or cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted with one to three halogen atoms;
- 5 R^{32} is hydrogen or alkyl wherein the alkyl is optionally substituted with halo.
- R^{33} is hydrogen or alkyl;
- R^{34} is hydrogen or alkyl;
- R^{35} is hydrogen, alkyl, OR^{3a} or $-NHR^{3a}$;
- R^{36} is hydrogen, alkyl, haloalkyl, or C_3 - C_6 cycloalkyl wherein the cycloalkyl is
- 10 optionally substituted with alkyl, haloalkyl, or 1 or 2 halogen atoms;
- R^{3a} and R^{3b} are independently hydrogen, alkyl or R^{3a} and R^{3b} combine with the nitrogen atom to which they are attached to form a four to six member heterocyclic ring optionally containing an oxygen or a nitrogen atom in the ring;
- or a pharmaceutically acceptable salt, isomer, or mixture thereof.
- 15 In certain embodiment, the ASK1 inhibitor is a compound having the structure of formula (III), wherein:
- R^{31} is C_1 - C_3 alkyl or C_3 - C_6 cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted with one to three halogen atoms;
- R^{32} is hydrogen or C_1 - C_6 alkyl wherein the alkyl is optionally substituted with
- 20 halo.
- R^{33} is hydrogen or C_1 - C_3 alkyl;
- R^{34} is hydrogen or C_1 - C_3 alkyl;
- R^{35} is hydrogen, C_1 - C_3 alkyl, OR^{3a} or $-NHR^{3a}$;
- R^{36} is hydrogen, C_1 - C_3 alkyl, C_1 - C_3 haloalkyl, or C_3 - C_6 cycloalkyl wherein the
- 25 cycloalkyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 haloalkyl, or 1 or 2 halogen atoms;
- R^{3a} and R^{3b} are independently hydrogen, C_1 - C_3 alkyl or R^{3a} and R^{3b} combine with the nitrogen atom to which they are attached to form a four to six member heterocyclic ring optionally containing an oxygen or a nitrogen atom in the ring;

or a pharmaceutically acceptable salt, isomer, or mixture thereof.

Exemplary compounds of Formula (III) for use in the methods and pharmaceutical compositions described herein can be found in U.S. Patent Application Publication No. 2014/0179663, which is incorporated herein by reference in its entirety.

5 In some embodiments, the ASK 1 inhibitor are the compounds described in U.S. Patent Application Publication Nos. 2007/0276050, 2011/0009410, 2013/0197037, 2013/0197037, and 2014/0179663, 2014/0038957, 2014/0018370, 2009/0318425, 2011/0077235, 2012/0316194, U.S. Patent No. 8,263,595, U.S. Provisional Patent Application No. 61/918,784, and PCT Patent Application Publication No. 2011/041293;
10 all of which are incorporated herein by reference in their entirety. In certain embodiments, the ASK1 inhibitor is:



or a pharmaceutically acceptable salt, isomer, or a mixture thereof. Compounds 1, 2, 3, 4, and 5 may be synthesized and characterized using the commonly used methods or those described in U.S. Patent Application Publication Nos. 2011/0009410 and
5 2013/0197037. In one embodiment, the ASK1 inhibitor is Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiment, the ASK1 inhibitor is Compound 2 or a pharmaceutically acceptable salt thereof. In further embodiment, the ASK1 inhibitor is Compound 3 or a pharmaceutically acceptable salt thereof. In some further embodiment, the ASK1 inhibitor is Compound 4 or a pharmaceutically
10 acceptable salt thereof. In certain further embodiment, the ASK1 inhibitor is Compound 5 or a pharmaceutically acceptable salt thereof.

The compounds of the present application may be represented by structures or chemical names. Also, the compounds may be named using the nomenclature systems and symbols that are commonly recognized in the art of chemistry including; for
15 example, ChemBioDraw Ultra 12.0, Chemical Abstract Service (CAS), and International Union of Pure and Applied Chemistry (IUPAC). By way of example, Compound 3 may also be referred to as 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide, 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-N-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide, or 5-
20 (4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide. Unless stated otherwise, the compounds described herein are named using ChemBioDraw Ultra 12.0; accordingly, Compound 1 may be referred to as 3-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)benzamide, Compound 2 may be referred to as 3-(4-cyclopropyl-1H-
25 imidazol-1-yl)-N-(6-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide, Compound 3 may be referred to as 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide, Compound 4 may be referred to as 4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(3-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)phenyl)picolinamide, and Compound 5 may be
30 referred to as (S)-5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-yl)benzamide.

FXR Agonist

Farnesoid X receptors are known to be expressed in liver, intestine, kidney and adrenal tissues. Activated FXR translocates to the cell nucleus and forms a heterodimer with retinoid X receptor (RXR). The dimer binds to hormone response elements on DNA causing, among other effects, a suppression of cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis from cholesterol, and stimulation of intestinal bile acid binding protein (IBABP). Both CYP7A1 and IBABP are involved in homeostasis of bile acid and cholesterol. A FXR agonist for use in the methods and pharmaceutical compositions disclosed herein may be any chemical compound or biological molecule (e.g., a protein or antibody) capable of binding and activating FXR. For example, GW4064 (3-(2,6-Dichlorophenyl)-4-(3'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole) and bile acids such as chenodeoxycholic acid (CDCA), lithocholic acid (LCA) and deoxycholic acid (DCA) are known to act as agonists of FXR. Additional examples of FXR agonist may be found in U.S. Publication Nos. 20100184809, 20100210660, 2012 0232116, 20140221659, 20140039007, 20140187633, 20140134262, and 20140057886. All publications cited in the application are incorporated by reference in their entirety.

It is suggested that FXR is a nuclear bile acid sensor that modulates the synthetic output of bile acids in the liver and their recycling in the intestine (by regulating bile acid binding proteins). Beyond bile acid physiology, FXR may be involved in the regulation of many diverse physiological processes which are relevant in the etiology and for the treatment of diseases as diverse as cholesterol gallstones, metabolic disorders such as Type II Diabetes, dyslipidemias or obesity, chronic inflammatory diseases such as inflammatory bowel diseases or chronic intrahepatic forms of cholestasis and many others diseases (see Claudel et al., *Arteriosclerosis, Thrombosis, and Vascular Biology* 2005 vol. 25, No. 10, 2020-2030; Westin et al., *Mini Review Medicinal Chemistry* 2005 vol. 5, No. 8, 719-727).

FXR regulates a complex pattern of response genes in the liver. The gene products have impact on diverse physiological processes. In the course of functional analysis of FXR, the first regulatory network that was analyzed was the regulation of bile acid synthesis. While the LXRs induce the key enzyme of the conversion of cholesterol into bile acids, Cyp7A1, via the induction of the regulatory nuclear receptor LRH-1,

FXR represses the induction of Cyp7A1 via the upregulation of mRNA encoding SHP, a further nuclear receptor that is dominant repressive over LRH-1. Since FXR binds the end products of this pathway, primary bile acids such as cholic acid (CA) or chenodeoxycholic acid (CDCA), this can be regarded as an example of feedback inhibition on the gene expression level (Goodwin et al., *Molecular Cell* 2000, vol. 6 No. 3, 517-526; Lu et al., *Molecular Cell* 2000, vol. 6, No. 3, 507-515). Parallel to the repression of bile acid synthesis via SHP, FXR induces a range of so-called ABC (for ATP-binding cassette) transporters that are responsible for the export of toxic bile acids from the hepatocyte cytosol into the canaliculi, the small bile duct ramifications where the bile originates. This hepatoprotective function of FXR became first apparent with the analysis of FXR knockout mice (Sinai et al., *Cell* 2000, vol. 102, No. 6, 731-744) where under- or overexpression of several ABC-transporters in the liver was shown. Further detailed analysis revealed that the major bile salt excretory pump BSEP or ABCB11 (Ananthanarayanan et al., *Journal of Biological Chemistry* 2001, vol. 276, No. 31, 28857-28865; Plass et al., *Hepatology* 2002, vol. 35 No. 3, 589-96) as well as the key enzyme which mediates lipid transfer from lipoproteins to phospholipids, PLTP (Urizar et al., *Journal of Biological Chemistry* 2000, vol. 275, No. 50, 39313-39317), and the two key canalicular membrane transporters for phospholipids, MRP-2 (ABCC4) (Kast et al., *Journal of Biological Chemistry* 2002, vol. 277, No.4, 2908-2915) and MDR-3 (ABCB4) (Huang et al., *Journal of Biological Chemistry* 2003, vol. 278, No. 51, 51085-51090) are direct targets for ligand-directed transcriptional activation by FXR (see Miyata, *Journal of Pharmacology and Experimental Therapeutics* 2005, vol. 312, No. 2, 759-766; Rizzo et al., *Current Drug Targets - Immune, Endocrine & Metabolic Disorders* 2005, vol. 5, No. 3, 289-303.).

25 **Dosing and Administration**

While it is possible for an active ingredient to be administered alone, it may be preferable to present them as pharmaceutical formulations or pharmaceutical compositions as described below. The formulations, both for veterinary and for human use, of the disclosure comprise at least one of the active ingredients, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.

Each of the active ingredients can be formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets can contain excipients, glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986). Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH of the formulations ranges from about 3 to about 11, but is ordinarily about 7 to 10.

The therapeutically effective amount of active ingredient can be readily determined by a skilled clinician using conventional dose escalation studies. Typically, the active ingredient will be administered in a dose from 0.01 milligrams to 2 grams. In one embodiment, the dosage will be from about 10 milligrams to 450 milligrams. In another embodiment, the dosage will be from about 25 to about 250 milligrams. In another embodiment, the dosage will be about 50 or 100 milligrams. In one embodiment, the dosage will be about 100 milligrams. It is contemplated that the active ingredient may be administered once, twice or three times a day. Also, the active ingredient may be administered once or twice a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

The pharmaceutical composition for the active ingredient can include those suitable for the foregoing administration routes. The formulations can conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Formulations suitable for oral administration can be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active

ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste. In certain embodiments, the active ingredient may be administered as a subcutaneous injection.

5 A tablet can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, or surface active agent. Molded tablets may be made by molding in a suitable machine a mixture of the
10 powdered active ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.

 The active ingredient can be administered by any route appropriate to the condition. Suitable routes include oral, rectal, nasal, topical (including buccal and
15 sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient. In certain embodiments, the active ingredients are orally bioavailable and can therefore be dosed orally. In one embodiment, the patient is human.

20 When used in combination in the methods disclosed herein, the ASK1 inhibitor and the FXR agonist can be administered together in a single pharmaceutical composition or separately (either concurrently or sequentially) in more than one pharmaceutical composition. In certain embodiments, the ASK1 inhibitor and the FXR agonist are administered together. In other embodiments, the ASK1 inhibitor and the
25 FXR agonist are administered separately. In some aspects, the ASK1 inhibitor is administered prior to the FXR agonist. In some aspects, the FXR agonist is administered prior to the ASK1 inhibitor. When administered separately, the ASK1 inhibitor and the FXR agonist can be administered to the patient by the same or different routes of delivery.

30

Pharmaceutical Compositions

The pharmaceutical compositions of the disclosure provide for an effective amount of an ASK1 inhibitor and an effective amount of a FXR agonist.

When used for oral use for example, tablets, troches, lozenges, aqueous or oil
5 suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or
elixirs may be prepared. Compositions intended for oral use may be prepared according
to any method known to the art for the manufacture of pharmaceutical compositions and
such compositions may contain one or more agents including sweetening agents,
flavoring agents, coloring agents and preserving agents, in order to provide a palatable
10 preparation. Tablets containing the active ingredient in admixture with non-toxic
pharmaceutically acceptable excipient which are suitable for manufacture of tablets are
acceptable. These excipients may be, for example, inert diluents, such as, for example,
calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium,
povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as,
15 for example, maize starch, or alginic acid; binding agents, such as, for example,
cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents,
such as, for example, magnesium stearate, stearic acid or talc. Tablets may be uncoated
or may be coated by known techniques including microencapsulation to delay
disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained
20 action over a longer period. For example, a time delay material such as, for example,
glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

Formulations for oral use may be also presented as hard gelatin capsules where
the active ingredient is mixed with an inert solid diluent, for example calcium phosphate
or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or
25 an oil medium, such as, for example, peanut oil, liquid paraffin or olive oil.

Aqueous suspensions of the disclosure contain the active materials in admixture
with excipients suitable for the manufacture of aqueous suspensions. Such excipients
include a suspending agent, such as, for example, sodium carboxymethylcellulose,
methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone,
30 gum tragacanth and gum acacia, and dispersing or wetting agents such as, for example, a
naturally occurring phosphatide (*e.g.*, lecithin), a condensation product of an alkylene

oxide with a fatty acid (*e.g.*, polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (*e.g.*, heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (*e.g.*, polyoxyethylene sorbitan monooleate). The aqueous
5 suspension may also contain one or more preservatives such as, for example, ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as, for example, sucrose or saccharin.

Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as, for example, arachis oil, olive oil, sesame oil or coconut oil, or in
10 a mineral oil such as, for example, liquid paraffin. The oral suspensions may contain a thickening agent, such as, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as, for example, those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as, for example, ascorbic acid.

15 Dispersible powders and granules of the disclosure suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring
20 agents, may also be present.

The pharmaceutical compositions of the disclosure may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as, for example, olive oil or arachis oil, a mineral oil, such as, for example, liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as, for
25 example, gum acacia and gum tragacanth, naturally occurring phosphatides, such as, for example, soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as, for example, sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as, for example, polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups
30 and elixirs may be formulated with sweetening agents, such as, for example, glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.

The pharmaceutical compositions of the disclosure may be in the form of a sterile injectable preparation, such as, for example, a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned
5 above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as, for example, a solution in 1,3-butane-diol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be
10 employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as, for example, oleic acid may likewise be used in the preparation of injectables.

The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the
15 particular mode of administration, such as oral administration or subcutaneous injection. For example, a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight:weight). The pharmaceutical composition can be
20 prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain from about 3 to 500 μg of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur. When formulated for subcutaneous administration, the formulation is typically administered about twice a month over a
25 period of from about two to about four months.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include
30 suspending agents and thickening agents.


The formulations can be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized)

condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit daily sub-
5 dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.

In one embodiment, the ASK1 inhibitor and the FXR agonist may be administered together in a combination formulation or in separate pharmaceutical compositions, where each inhibitor may be formulated in any suitable dosage form. In certain embodiments, the methods provided herein comprise administering separately a
10 pharmaceutical composition comprising an ASK1 inhibitor and a pharmaceutically acceptable carrier or excipient and a pharmaceutical composition comprising a FXR agonist and a pharmaceutically acceptable carrier or excipient. Combination formulations according to the present disclosure comprise an ASK1 inhibitor and a FXR agonist together with one or more pharmaceutically acceptable carriers or excipients and
15 optionally other therapeutic agents. Combination formulations containing the active ingredient may be in any form suitable for the intended method of administration.

What is claimed is:

1. A method of treating and/or preventing liver disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an ASK1 inhibitor in combination with a therapeutically effective amount of a second therapeutic agent.
2. The method of claim 1, wherein the liver disease is selected from chronic liver disease, metabolic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, or primary sclerosing cholangitis (PSC).
3. The method of any one of claims 1-2, wherein the ASK1 inhibitor is a compound of formula (I):



(I)

wherein:

R^1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to three substituents selected from halo, oxo, alkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, $-\text{NO}_2$, R^6 , $-\text{C}(\text{O})-\text{R}^6$, $-\text{OC}(\text{O})-\text{R}^6-\text{C}(\text{O})-\text{O}-\text{R}^6$, $\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{OC}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}-\text{R}^6$, $-\text{S}(=\text{O})-\text{R}^6$, $-\text{S}(=\text{O})_2\text{R}^6$, $-\text{S}(=\text{O})_2-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}(=\text{O})_2-\text{O}-\text{R}^6$, $-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{R}^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{O}-\text{R}^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{N}(\text{R}^6)-\text{S}(=\text{O})_2-\text{R}^6$, $-\text{CN}$, and $-\text{O}-\text{R}^6$, and wherein the alkyl, cycloalkyl, heterocyclyl, phenyl, and phenoxy are optionally substituted by from one to three substituents selected from alkyl, cycloalkyl, alkoxy, hydroxyl, and halo; wherein R^6 and R^7 are independently selected from the group consisting of hydrogen, $\text{C}_1\text{-C}_{15}$ alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, all of which are optionally substituted with from one to three substituents selected from halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, $-\text{CN}$, lower alkoxy, $-\text{CF}_3$, aryl, and heteroaryl; or

R^6 and R^7 when taken together with the nitrogen to which they are attached form a heterocycle;

R^2 is hydrogen, halo, cyano, alkoxy, or alkyl optionally substituted by halo;

R^3 is aryl, heteroaryl, or heterocyclyl, wherein the aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to five substituents selected from alkyl, alkoxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, oxo, $-\text{NO}_2$, haloalkyl, haloalkoxy, $-\text{CN}$, $-\text{O}-R^6$, $-\text{O}-\text{C}(\text{O})-R^6$, $-\text{O}-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}-R^6$, $-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}(\text{=O})-R^6$, $-\text{S}(\text{=O})_2R^6$, $-\text{S}(\text{=O})_2-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}(\text{=O})_2-\text{O}-R^6$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-R^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{O}-R^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{C}(\text{O})-R^6$, $-\text{C}(\text{O})-R^6$, $-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, and $-\text{N}(\text{R}^6)-\text{S}(\text{=O})_2-R^7$, wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally substituted with from one to five substituents selected from halo, oxo, $-\text{NO}_2$, alkyl, haloalkyl, haloalkoxy, $-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{C}(\text{O})-R^6$, $-\text{C}(\text{O})-\text{O}-R^6$, $-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{CN}$, $-\text{O}-R^6$, cycloalkyl, aryl, heteroaryl and heterocyclyl; with the proviso that the heteroaryl or heterocyclyl moiety includes at least one ring nitrogen atom;


X^1 , X^2 , X^3 , X^4 , X^5 , X^6 , X^7 and X^8 are independently $\text{C}(\text{R}^4)$ or N , in which each R^4 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, $-\text{NO}_2$, haloalkyl, haloalkoxy, $-\text{CN}$, $-\text{O}-R^6$, $-\text{S}-R^6$, $-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}(\text{=O})-R^6$, $-\text{S}(\text{=O})_2R^6$, $-\text{S}(\text{=O})_2-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{S}(\text{=O})_2-\text{O}-R^6$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-R^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{O}-R^7$, $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{C}(\text{O})-R^6$, $-\text{C}(\text{O})-\text{O}-R^6$, $-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, or $-\text{N}(\text{R}^6)-\text{S}(\text{=O})_2-R^7$, wherein the alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl is further optionally substituted with from one to five substituents selected from halo, oxo, $-\text{NO}_2$, $-\text{CF}_3$, $-\text{O}-\text{CF}_3$, $-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{C}(\text{O})-R^6$, $-\text{C}(\text{O})-\text{O}-R^7$, $-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$, $-\text{CN}$, $-\text{O}-R^6$; or

X^5 and X^6 or X^6 and X^7 are joined to provide optionally substituted fused aryl or optionally substituted fused heteroaryl; and

with the proviso that at least one of X^2 , X^3 , and X^4 is $\text{C}(\text{R}^4)$; at least two of X^5 , X^6 , X^7 , and X^8 are $\text{C}(\text{R}^4)$; and at least one of X^2 , X^3 , X^4 , X^5 , X^6 , X^7 and X^8 is N ;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

4. The method of any of claims 1-2, wherein the ASK1 inhibitor is a compound of formula (II):



(II)

wherein:

R^{21} is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to four substituents selected from the group consisting of halo, hydroxyl, oxo, alkyl, cycloalkyl, heterocyclyl, aryl, aryloxy, NO_2 , R^{26} , $\text{C}(\text{O})R^{26}$, $\text{OC}(\text{O})R^{26}\text{C}(\text{O})\text{OR}^{26}$, $\text{C}(\text{O})\text{N}(R^{26})(R^{27})$, $\text{OC}(\text{O})\text{N}(R^{26})(R^{27})$, SR^{26} , $\text{S}(\text{=O})R^{26}$, $\text{S}(\text{=O})_2R^{26}$, $\text{S}(\text{=O})_2\text{N}(R^{26})(R^{27})$, $\text{S}(\text{=O})_2\text{OR}^{26}$, $\text{N}(R^{26})(R^{27})$, $\text{N}(R^{26})\text{C}(\text{O})R^{27}$, $\text{N}(R^{26})\text{C}(\text{O})\text{OR}^{27}$, $\text{N}(R^{26})\text{C}(\text{O})\text{N}(R^{26})(R^{27})$, $\text{N}(R^{26})\text{S}(\text{=O})_2R^{26}$, CN , and OR^{26} , wherein the alkyl, cycloalkyl, heterocyclyl, aryl, and aryloxy are optionally substituted with from one to three substituents selected from alkyl, cycloalkyl, alkoxy, hydroxyl, and halo;

R^{26} and R^{27} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with from one to three substituents selected from halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN , lower alkoxy, CF_3 , aryl, and heteroaryl; or

R^{26} and R^{27} when taken together with the nitrogen to which they are attached form a heterocycle;

R^{22} is aryl, heteroaryl, or heterocyclyl, wherein the aryl, heteroaryl, and heterocyclyl are optionally substituted with from one to five substituents selected from alkyl, alkoxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, oxo, NO_2 , haloalkyl, haloalkoxy, CN , OR^{26} , $\text{OC}(\text{O})R^{26}$, $\text{OC}(\text{O})\text{N}(R^{26})(R^{27})$, SR^{26} , $\text{N}(R^{26})(R^{27})$, $\text{S}(\text{=O})R^{26}$, $\text{S}(\text{=O})_2R^{26}$, $\text{S}(\text{=O})_2\text{N}(R^{26})(R^{27})$, $\text{S}(\text{=O})_2\text{OR}^{26}$, $\text{N}(R^{26})\text{C}(\text{O})R^{27}$, $\text{N}(R^{26})\text{C}(\text{O})\text{OR}^{27}$, $\text{N}(R^{26})\text{C}(\text{O})\text{N}(R^{26})(R^{27})$, $\text{C}(\text{O})R^{26}$, $\text{C}(\text{O})\text{OR}^{26}$, $\text{C}(\text{O})\text{N}(R^{26})(R^{27})$, and $\text{N}(R^{26})\text{S}(\text{=O})_2R^{27}$, and wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted with one or more substituents selected from halo, oxo, NO_2 , alkyl, haloalkyl, haloalkoxy, $\text{N}(R^{26})(R^{27})$, $\text{C}(\text{O})R^{26}$, $\text{C}(\text{O})\text{OR}^{26}$, $\text{C}(\text{O})\text{N}(R^{26})(R^{27})$, CN , OR^{26} , cycloalkyl, aryl, heteroaryl and heterocyclyl; with the proviso that the heteroaryl or heterocyclyl moiety includes at least one ring nitrogen atom;


R^{24} and R^{25} are independently hydrogen, halo, cyano, alkyl, alkoxy, or cycloalkyl, wherein the alkyl, alkoxy, and cycloalkyl are optionally substituted by halo or cycloalkyl;

X^{21} and X^{25} are independently $\text{C}(R^{23})$ or N , wherein each R^{23} is independently hydrogen, halo, alkyl, alkoxy or cycloalkyl, wherein the alkyl and cycloalkyl are optionally substituted with from one to five substituents selected from halo, oxo, CF_3 , OCF_3 , $\text{N}(R^{26})(R^{27})$, $\text{C}(\text{O})R^{26}$, $\text{C}(\text{O})\text{OR}^{27}$, $\text{C}(\text{O})\text{N}(R^{26})(R^{27})$, CN , and OR^{26} ; and

X^{22} , X^{23} and X^{24} are independently C(R^{23}), N, O, or S; with the proviso that at least one of X^{22} , X^{23} , and X^{24} is C(R^{23}); and only one of X^{22} , X^{23} , and X^{24} is O or S;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

5. The method of any of claims 1-2, wherein the ASK1 inhibitor is a compound of formula (III):



(III)

wherein:

R^{31} is C₁-C₃ alkyl or C₃-C₆ cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted with one to three halogen atoms;

R^{32} is hydrogen or C₁-C₆ alkyl wherein the alkyl is optionally substituted with halo.

R^{33} is hydrogen or C₁-C₃ alkyl;

R^{34} is hydrogen or C₁-C₃ alkyl;

R^{35} is hydrogen, C₁-C₃ alkyl, OR^{3a} or -NHR^{3a};

R^{36} is hydrogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, or C₃-C₆ cycloalkyl wherein the cycloalkyl is optionally substituted with C₁-C₃ alkyl, C₁-C₃ haloalkyl, or 1 or 2 halogen atoms;

R^{3a} and R^{3b} are independently hydrogen, C₁-C₃ alkyl or R^{3a} and R^{3b} combine with the nitrogen atom to which they are attached to form a four to six member heterocyclic ring optionally containing an oxygen or a nitrogen atom in the ring;

or a pharmaceutically acceptable salt, isomer, or mixture thereof.

6. The method of any one of claims 1-5, wherein the second therapeutic agent is a FXR agonist.

7. The method of any one of claims 1-6, wherein the ASK1 inhibitor and the FXR agonist are administered together.

8. The method of any one of claims 1-7, wherein the ASK1 inhibitor and the FXR agonist are administered separately.

9. A pharmaceutical composition comprising a therapeutically effective amount of an ASK1 inhibitor and a therapeutically effective amount of a FXR agonist.
10. The pharmaceutical composition of claim 9, further comprising a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/051529

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/42 A61K31/4439 A61K45/06
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2013/197037 A1 (NOTTE GREGORY [US]) 1 August 2013 (2013-08-01)	1,3
Y	The preferred compound N.3 shown in page 27 of the present application, as ASK1 inhibitor for the treatment of liver fibrosis, alone or in combination with other agents: see claims 1, 4 and paragraph 25, and see the combination mentioned in paragraphs 58, 59	1-3,6-10
X	US 2009/318425 A1 (CHANG EDCON [US] ET AL) 24 December 2009 (2009-12-24)	1
Y	ASK1 inhibitors, alone and in combination with other agents, for use in the treatment of liver disease: see par 2, 15, 33-36, 337, 341, 366; claims 62, 66, 70 and see the combination therapies indicated in paragraphs 376-410	1-3,6-10
	----- -/-	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 December 2015

Date of mailing of the international search report

03/03/2016

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Veronese, Andrea

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2015/051529

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SHUHEI YOSHIDA ET AL: "1215: Pharmacologic inhibition of ASK1 attenuates hepatocyte apoptosis and limits hepatotoxin-induced liverfibrosis progression in mice", HEPATOLOGY, vol. 56, no. Suppl. 1, 1 October 2012 (2012-10-01), - 13 November 2012 (2012-11-13), pages 771A-772A, XP055208533, USA ISSN: 0270-9139, DOI: 10.1002/hep.26040 ASK-1 inhibition, obtained using a small molecule inhibiting ASK1, attenuates hepatocyte apoptosis and liver fibrosis in animals -----	1-3,6-10
Y	NORMAN PETER: "Evaluation of WO2012003387, Gilead's ASK1 inhibitors.", EXPERT OPINION ON THERAPEUTIC PATENTS APR 2012, vol. 22, no. 4, April 2012 (2012-04), pages 455-459, XP002751896, ISSN: 1744-7674 ASK1 inhibitors, including the preferred compound 1 of the present application, for use in the treatment of liver disease: see figure 1 and page 457, right hand side. -----	1-3,6-10
Y	ADORINI L ET AL: "Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis", DRUG DISCOVERY TODAY 2012 ELSEVIER LTD GBR, vol. 17, no. 17-18, September 2012 (2012-09), pages 988-997, XP002751897, ISSN: 1359-6446 Farnesoid X receptor targeting using FXR agonists (such as GW-4064, and INT-747), for treating non-alcoholic steatohepatitis: see abstract and discussion ----- -/--	1-3,6-10

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2015/051529

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ZHANG S ET AL: "Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 51, no. 2, 1 August 2009 (2009-08-01), pages 380-388, XP026322329, ISSN: 0168-8278, DOI: 10.1016/J.JHEP.2009.03.025 [retrieved on 2009-05-18] WAY-362450, an FXR receptor agonist, attenuates liver inflammation and fibrosis in animal models: see abstract, results and discussion -----	1-3,6-10
Y	US 2003/203939 A1 (KLIEWER STEVEN ANTHONY [US] ET AL) 30 October 2003 (2003-10-30) FXR Agonists for the treatment of liver disease: see claims -----	1-3,6-10
T	SCHWABL P ET AL: "G18 : The FXR agonist PX20606 reduces liver damage, fibrosis and portal hypertension in cirrhotic rats", JOURNAL OF HEPATOLOGY, vol. 62, 2015, - 2015, XP029161382, ISSN: 0168-8278, DOI: 10.1016/S0168-8278(15)30106-9 The FXR agonist PX20606 reduces liver damage and liver fibrosis in animals -----	
Y	NEUSCHWANDER-TETRI BRENT A: "Farnesoid x receptor agonists: what they are and how they might be used in treating liver disease.", CURRENT GASTROENTEROLOGY REPORTS FEB 2012, vol. 14, no. 1, February 2012 (2012-02), pages 55-62, XP002751898, ISSN: 1534-312X FXR agonists for treating liver disease: see abstract and discussion -----	1-3,6-10
Y	WO 2005/032549 A1 (SMITHKLINE BEECHAM CORP [US]; JONES STACEY ANN [US]; LIU YAPING [US];) 14 April 2005 (2005-04-14) FXR agonists for treating liver disease: see claims and examples -----	1-3,6-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2015/051529

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

3(completely); 1, 2, 6-10(partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 3(completely); 1, 2, 6-10(partially)

Combination comprising an ASK1 inhibitor of formula (I) in combination with another agent, for use in the treatment of liver disease

2. claims: 4, 5(completely); 1, 2, 6-10(partially)

Combination comprising an ASK1 inhibitor of formula (II) and (III) in combination with another agent, for use in the treatment of liver disease

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2015/051529

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2013197037	A1	01-08-2013	AR 089818 A1 17-09-2014
		AU 2013201586 A1 15-08-2013	
		CA 2862030 A1 01-08-2013	
		CL 2014001988 A1 03-11-2014	
		CN 104080771 A 01-10-2014	
		CO 7061073 A2 19-09-2014	
		CR 20140405 A 27-11-2014	
		DK 2807151 T3 22-02-2016	
		EA 201491283 A1 30-12-2014	
		EP 2807151 A1 03-12-2014	
		ES 2558203 T3 02-02-2016	
		HK 1204324 A1 13-11-2015	
		HR P20151399 T1 29-01-2016	
		IL 233598 A 30-06-2015	
		JP 5770950 B2 26-08-2015	
		JP 2015508749 A 23-03-2015	
		KR 20140117609 A 07-10-2014	
		KR 20160004401 A 12-01-2016	
		MA 35861 B1 01-12-2014	
		MD 20140082 A2 31-01-2015	
		PE 18222014 A1 27-11-2014	
		PH 12014501697 A1 20-10-2014	
		PT 2807151 E 28-01-2016	
		SG 11201404348U A 28-08-2014	
		TW 201334782 A 01-09-2013	
		TW 201441213 A 01-11-2014	
		US 2013197037 A1 01-08-2013	
		US 2014228411 A1 14-08-2014	
		US 2014228412 A1 14-08-2014	
		UY 34573 A 28-06-2013	
		WO 2013112741 A1 01-08-2013	
US 2009318425	A1	24-12-2009	US 2009318425 A1 24-12-2009
			WO 2010008843 A1 21-01-2010
US 2003203939	A1	30-10-2003	AU 2003226283 A1 10-11-2003
			EP 1501506 A1 02-02-2005
			US 2003203939 A1 30-10-2003
			WO 03090745 A1 06-11-2003
WO 2005032549	A1	14-04-2005	EP 1696910 A1 06-09-2006
			US 2007015796 A1 18-01-2007
			US 2011021475 A1 27-01-2011
			WO 2005032549 A1 14-04-2005